Global Hydromorphone Hydrochloride (HCL) Injections Market Size, Share, and Trends Analysis Report, By Application (Surgical Procedures, Road Accidents, Sickle Cell Disease, and Others) and By End-user (Hospitals, Community Health Centers, and Speciality Clinics), Forecast (2022-2028)

The global hydromorphone hydrochloride (HCL) injections market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). Hydromorphane HCL injections are the opioid pain relieving medication use for the treatment of moderate to severe pain due to several reasons including road injuries, post surgical pain, and sickle cell disease, among others. It works by acting on certain part of brain to stop sending pain signals. The major factor attributing to the growth of the global hydromorphone HCL injections market is the rising prevalence of sickle cell disease across the globe. According to the American Society of Hematology (ASH), sickle cell disease is a most common type of inherited blood disorder causing nerve damage. Around 70,000 to 1,00,000 people are affected by sickle cell disease in the US alone in 2021. Sickle cell disease shows several symptoms including anemia, yellow eyes, painful swelling of hands & feet, frequent pain episodes, strokes, and many others.

The application of hydromorphone HCL injections are also increasing for relieving pain during or after major surgical procedures. According to the National Center for biotechnology information (NCBI), around 234 million major surgical procedures are performed globally every year. Furthermore, increasing usage of hydromorphone HCL injections for relieving pain due to increasing road injuries is also supporting the growth of the market. According to the report published by the World Health Organization (WHO) in June 2021, around 20 million to 50 million people suffer from non-fatal injuries as a result of road accidents every year causing pain in affected body parts. Thus, increasing the demand for hydromorphone HCL injections.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Application
  • By End-user
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Novartis International AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Baxter International Inc., and Hikma Pharmaceuticals PLC, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Hydromorphone Hydrochloride Injections Market Report by Segment

By Application

• Surgical Procedures
• Road Accidents
• Sickle Cell Disease
• Others

By End-user

• Hospitals
• Community Health Centers
• Speciality Clinics

Global Hydromorphone Hydrochloride Injections Market Report by Region

North America

• The United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa